http://142-54-23-223.fusionmedialtd.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 17 Jul 2026 01:22:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://142-54-23-223.fusionmedialtd.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Camurus%27+NDA+resubmission+for+CAM2029+in+acromegaly+accepted+for+review+by+the+US+FDA/26781059.html <div class="xn-content"> <p><i>PDUFA target action date set to <chron>18 December 2026</chron></i></p><p><span class="legendSpanClass"><location value="LU/se..lund" idsrc="xmltag.org" >LUND, Sweden</location></span>, <span class="legendSpanClass"><chron>July 17, 2026</chron></span> /PRNewswire/ -- <span value="Stockholm:CAMX" idsrc="xmltag.org" >Camurus</span> (NASDAQ STO: CAMX) today announced that the <span value="ACORN:0682203466" idsrc="xmltag.org" >US Food and Drug Administration</span> (FDA) has accepted for review the resubmission of the New Drug Application (NDA) for CAM2029, octreotide extended-release injection, for the treatment of patients with acromegaly. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of <chron>18 December 2026</chron>.</p> <p>The resubmission follows the Complete Response Letter (CRL) issued by the FDA on <chron>10 June 2026</chron>, which related http://www.streetinsider.com/Press+Releases/Camurus%27+NDA+resubmission+for+CAM2029+in+acromegaly+accepted+for+review+by+the+US+FDA/26781059.html Fri, 17 Jul 2026 01:22:00 -0400 A.06822034 CAMX CAMX CAMX CAMX O.01705570 O.20026344 http://www.streetinsider.com/Press+Releases/Camurus%27+NDA+resubmission+for+CAM2029+in+acromegaly+accepted+for+review+by+the+US+FDA/26781059.html <div class="xn-content"> <p><i>PDUFA target action date set to <chron>18 December 2026</chron></i></p><p><span class="legendSpanClass"><location value="LU/se..lund" idsrc="xmltag.org" >LUND, Sweden</location></span>, <span class="legendSpanClass"><chron>July 17, 2026</chron></span> /PRNewswire/ -- <span value="Stockholm:CAMX" idsrc="xmltag.org" >Camurus</span> (NASDAQ STO: CAMX) today announced that the <span value="ACORN:0682203466" idsrc="xmltag.org" >US Food and Drug Administration</span> (FDA) has accepted for review the resubmission of the New Drug Application (NDA) for CAM2029, octreotide extended-release injection, for the treatment of patients with acromegaly. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of <chron>18 December 2026</chron>.</p> <p>The resubmission follows the Complete Response Letter (CRL) issued by the FDA on <chron>10 June 2026</chron>, which related http://www.streetinsider.com/Press+Releases/Camurus%27+NDA+resubmission+for+CAM2029+in+acromegaly+accepted+for+review+by+the+US+FDA/26781059.html Fri, 17 Jul 2026 01:22:00 -0400 A.06822034 CAMX CAMX CAMX CAMX O.01705570 O.20026344 http://www.streetinsider.com/Press+Releases/Camurus%27+NDA+resubmission+for+CAM2029+in+acromegaly+accepted+for+review+by+the+US+FDA/26781059.html <div class="xn-content"> <p><i>PDUFA target action date set to <chron>18 December 2026</chron></i></p><p><span class="legendSpanClass"><location value="LU/se..lund" idsrc="xmltag.org" >LUND, Sweden</location></span>, <span class="legendSpanClass"><chron>July 17, 2026</chron></span> /PRNewswire/ -- <span value="Stockholm:CAMX" idsrc="xmltag.org" >Camurus</span> (NASDAQ STO: CAMX) today announced that the <span value="ACORN:0682203466" idsrc="xmltag.org" >US Food and Drug Administration</span> (FDA) has accepted for review the resubmission of the New Drug Application (NDA) for CAM2029, octreotide extended-release injection, for the treatment of patients with acromegaly. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of <chron>18 December 2026</chron>.</p> <p>The resubmission follows the Complete Response Letter (CRL) issued by the FDA on <chron>10 June 2026</chron>, which related http://www.streetinsider.com/Press+Releases/Camurus%27+NDA+resubmission+for+CAM2029+in+acromegaly+accepted+for+review+by+the+US+FDA/26781059.html Fri, 17 Jul 2026 01:22:00 -0400 A.06822034 CAMX CAMX CAMX CAMX O.01705570 O.20026344 http://www.streetinsider.com/Press+Releases/Camurus%27+NDA+resubmission+for+CAM2029+in+acromegaly+accepted+for+review+by+the+US+FDA/26781059.html <div class="xn-content"> <p><i>PDUFA target action date set to <chron>18 December 2026</chron></i></p><p><span class="legendSpanClass"><location value="LU/se..lund" idsrc="xmltag.org" >LUND, Sweden</location></span>, <span class="legendSpanClass"><chron>July 17, 2026</chron></span> /PRNewswire/ -- <span value="Stockholm:CAMX" idsrc="xmltag.org" >Camurus</span> (NASDAQ STO: CAMX) today announced that the <span value="ACORN:0682203466" idsrc="xmltag.org" >US Food and Drug Administration</span> (FDA) has accepted for review the resubmission of the New Drug Application (NDA) for CAM2029, octreotide extended-release injection, for the treatment of patients with acromegaly. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of <chron>18 December 2026</chron>.</p> <p>The resubmission follows the Complete Response Letter (CRL) issued by the FDA on <chron>10 June 2026</chron>, which related http://www.streetinsider.com/Press+Releases/Camurus%27+NDA+resubmission+for+CAM2029+in+acromegaly+accepted+for+review+by+the+US+FDA/26781059.html Fri, 17 Jul 2026 01:22:00 -0400 A.06822034 CAMX CAMX CAMX CAMX O.01705570 O.20026344 http://www.streetinsider.com/Press+Releases/Camurus%27+NDA+resubmission+for+CAM2029+in+acromegaly+accepted+for+review+by+the+US+FDA/26781059.html <div class="xn-content"> <p><i>PDUFA target action date set to <chron>18 December 2026</chron></i></p><p><span class="legendSpanClass"><location value="LU/se..lund" idsrc="xmltag.org" >LUND, Sweden</location></span>, <span class="legendSpanClass"><chron>July 17, 2026</chron></span> /PRNewswire/ -- <span value="Stockholm:CAMX" idsrc="xmltag.org" >Camurus</span> (NASDAQ STO: CAMX) today announced that the <span value="ACORN:0682203466" idsrc="xmltag.org" >US Food and Drug Administration</span> (FDA) has accepted for review the resubmission of the New Drug Application (NDA) for CAM2029, octreotide extended-release injection, for the treatment of patients with acromegaly. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of <chron>18 December 2026</chron>.</p> <p>The resubmission follows the Complete Response Letter (CRL) issued by the FDA on <chron>10 June 2026</chron>, which related http://www.streetinsider.com/Press+Releases/Camurus%27+NDA+resubmission+for+CAM2029+in+acromegaly+accepted+for+review+by+the+US+FDA/26781059.html Fri, 17 Jul 2026 01:22:00 -0400 A.06822034 CAMX CAMX CAMX CAMX O.01705570 O.20026344 http://www.streetinsider.com/Press+Releases/Camurus%27+NDA+resubmission+for+CAM2029+in+acromegaly+accepted+for+review+by+the+US+FDA/26781059.html <div class="xn-content"> <p><i>PDUFA target action date set to <chron>18 December 2026</chron></i></p><p><span class="legendSpanClass"><location value="LU/se..lund" idsrc="xmltag.org" >LUND, Sweden</location></span>, <span class="legendSpanClass"><chron>July 17, 2026</chron></span> /PRNewswire/ -- <span value="Stockholm:CAMX" idsrc="xmltag.org" >Camurus</span> (NASDAQ STO: CAMX) today announced that the <span value="ACORN:0682203466" idsrc="xmltag.org" >US Food and Drug Administration</span> (FDA) has accepted for review the resubmission of the New Drug Application (NDA) for CAM2029, octreotide extended-release injection, for the treatment of patients with acromegaly. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of <chron>18 December 2026</chron>.</p> <p>The resubmission follows the Complete Response Letter (CRL) issued by the FDA on <chron>10 June 2026</chron>, which related http://www.streetinsider.com/Press+Releases/Camurus%27+NDA+resubmission+for+CAM2029+in+acromegaly+accepted+for+review+by+the+US+FDA/26781059.html Fri, 17 Jul 2026 01:22:00 -0400 A.06822034 CAMX CAMX CAMX CAMX O.01705570 O.20026344 http://www.streetinsider.com/Press+Releases/Camurus%27+NDA+resubmission+for+CAM2029+in+acromegaly+accepted+for+review+by+the+US+FDA/26781059.html <div class="xn-content"> <p><i>PDUFA target action date set to <chron>18 December 2026</chron></i></p><p><span class="legendSpanClass"><location value="LU/se..lund" idsrc="xmltag.org" >LUND, Sweden</location></span>, <span class="legendSpanClass"><chron>July 17, 2026</chron></span> /PRNewswire/ -- <span value="Stockholm:CAMX" idsrc="xmltag.org" >Camurus</span> (NASDAQ STO: CAMX) today announced that the <span value="ACORN:0682203466" idsrc="xmltag.org" >US Food and Drug Administration</span> (FDA) has accepted for review the resubmission of the New Drug Application (NDA) for CAM2029, octreotide extended-release injection, for the treatment of patients with acromegaly. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of <chron>18 December 2026</chron>.</p> <p>The resubmission follows the Complete Response Letter (CRL) issued by the FDA on <chron>10 June 2026</chron>, which related http://www.streetinsider.com/Press+Releases/Camurus%27+NDA+resubmission+for+CAM2029+in+acromegaly+accepted+for+review+by+the+US+FDA/26781059.html Fri, 17 Jul 2026 01:22:00 -0400 A.06822034 CAMX CAMX CAMX CAMX O.01705570 O.20026344 http://www.streetinsider.com/PRNewswire/Camurus%27+NDA+resubmission+for+CAM2029+in+acromegaly+accepted+for+review+by+the+US+FDA/26781059.html <div class="xn-content"> <p><i>PDUFA target action date set to <chron>18 December 2026</chron></i></p><p><span class="legendSpanClass"><location value="LU/se..lund" idsrc="xmltag.org" >LUND, Sweden</location></span>, <span class="legendSpanClass"><chron>July 17, 2026</chron></span> /PRNewswire/ -- <span value="Stockholm:CAMX" idsrc="xmltag.org" >Camurus</span> (NASDAQ STO: CAMX) today announced that the <span value="ACORN:0682203466" idsrc="xmltag.org" >US Food and Drug Administration</span> (FDA) has accepted for review the resubmission of the New Drug Application (NDA) for CAM2029, octreotide extended-release injection, for the treatment of patients with acromegaly. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of <chron>18 December 2026</chron>.</p> <p>The resubmission follows the Complete Response Letter (CRL) issued by the FDA on <chron>10 June 2026</chron>, which related http://www.streetinsider.com/PRNewswire/Camurus%27+NDA+resubmission+for+CAM2029+in+acromegaly+accepted+for+review+by+the+US+FDA/26781059.html Fri, 17 Jul 2026 01:22:00 -0400 A.06822034 CAMX CAMX CAMX CAMX O.01705570 O.20026344 http://www.streetinsider.com/PRNewswire/Camurus%27+NDA+resubmission+for+CAM2029+in+acromegaly+accepted+for+review+by+the+US+FDA/26781059.html <div class="xn-content"> <p><i>PDUFA target action date set to <chron>18 December 2026</chron></i></p><p><span class="legendSpanClass"><location value="LU/se..lund" idsrc="xmltag.org" >LUND, Sweden</location></span>, <span class="legendSpanClass"><chron>July 17, 2026</chron></span> /PRNewswire/ -- <span value="Stockholm:CAMX" idsrc="xmltag.org" >Camurus</span> (NASDAQ STO: CAMX) today announced that the <span value="ACORN:0682203466" idsrc="xmltag.org" >US Food and Drug Administration</span> (FDA) has accepted for review the resubmission of the New Drug Application (NDA) for CAM2029, octreotide extended-release injection, for the treatment of patients with acromegaly. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of <chron>18 December 2026</chron>.</p> <p>The resubmission follows the Complete Response Letter (CRL) issued by the FDA on <chron>10 June 2026</chron>, which related http://www.streetinsider.com/PRNewswire/Camurus%27+NDA+resubmission+for+CAM2029+in+acromegaly+accepted+for+review+by+the+US+FDA/26781059.html Fri, 17 Jul 2026 01:22:00 -0400 A.06822034 CAMX CAMX CAMX CAMX O.01705570 O.20026344 http://www.streetinsider.com/PRNewswire/Camurus%27+NDA+resubmission+for+CAM2029+in+acromegaly+accepted+for+review+by+the+US+FDA/26781059.html <div class="xn-content"> <p><i>PDUFA target action date set to <chron>18 December 2026</chron></i></p><p><span class="legendSpanClass"><location value="LU/se..lund" idsrc="xmltag.org" >LUND, Sweden</location></span>, <span class="legendSpanClass"><chron>July 17, 2026</chron></span> /PRNewswire/ -- <span value="Stockholm:CAMX" idsrc="xmltag.org" >Camurus</span> (NASDAQ STO: CAMX) today announced that the <span value="ACORN:0682203466" idsrc="xmltag.org" >US Food and Drug Administration</span> (FDA) has accepted for review the resubmission of the New Drug Application (NDA) for CAM2029, octreotide extended-release injection, for the treatment of patients with acromegaly. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of <chron>18 December 2026</chron>.</p> <p>The resubmission follows the Complete Response Letter (CRL) issued by the FDA on <chron>10 June 2026</chron>, which related http://www.streetinsider.com/PRNewswire/Camurus%27+NDA+resubmission+for+CAM2029+in+acromegaly+accepted+for+review+by+the+US+FDA/26781059.html Fri, 17 Jul 2026 01:22:00 -0400 A.06822034 CAMX CAMX CAMX CAMX O.01705570 O.20026344 http://www.streetinsider.com/PRNewswire/Camurus%27+NDA+resubmission+for+CAM2029+in+acromegaly+accepted+for+review+by+the+US+FDA/26781059.html <div class="xn-content"> <p><i>PDUFA target action date set to <chron>18 December 2026</chron></i></p><p><span class="legendSpanClass"><location value="LU/se..lund" idsrc="xmltag.org" >LUND, Sweden</location></span>, <span class="legendSpanClass"><chron>July 17, 2026</chron></span> /PRNewswire/ -- <span value="Stockholm:CAMX" idsrc="xmltag.org" >Camurus</span> (NASDAQ STO: CAMX) today announced that the <span value="ACORN:0682203466" idsrc="xmltag.org" >US Food and Drug Administration</span> (FDA) has accepted for review the resubmission of the New Drug Application (NDA) for CAM2029, octreotide extended-release injection, for the treatment of patients with acromegaly. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of <chron>18 December 2026</chron>.</p> <p>The resubmission follows the Complete Response Letter (CRL) issued by the FDA on <chron>10 June 2026</chron>, which related http://www.streetinsider.com/PRNewswire/Camurus%27+NDA+resubmission+for+CAM2029+in+acromegaly+accepted+for+review+by+the+US+FDA/26781059.html Fri, 17 Jul 2026 01:22:00 -0400 A.06822034 CAMX CAMX CAMX CAMX O.01705570 O.20026344 http://www.streetinsider.com/PRNewswire/Camurus%27+NDA+resubmission+for+CAM2029+in+acromegaly+accepted+for+review+by+the+US+FDA/26781059.html <div class="xn-content"> <p><i>PDUFA target action date set to <chron>18 December 2026</chron></i></p><p><span class="legendSpanClass"><location value="LU/se..lund" idsrc="xmltag.org" >LUND, Sweden</location></span>, <span class="legendSpanClass"><chron>July 17, 2026</chron></span> /PRNewswire/ -- <span value="Stockholm:CAMX" idsrc="xmltag.org" >Camurus</span> (NASDAQ STO: CAMX) today announced that the <span value="ACORN:0682203466" idsrc="xmltag.org" >US Food and Drug Administration</span> (FDA) has accepted for review the resubmission of the New Drug Application (NDA) for CAM2029, octreotide extended-release injection, for the treatment of patients with acromegaly. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of <chron>18 December 2026</chron>.</p> <p>The resubmission follows the Complete Response Letter (CRL) issued by the FDA on <chron>10 June 2026</chron>, which related http://www.streetinsider.com/PRNewswire/Camurus%27+NDA+resubmission+for+CAM2029+in+acromegaly+accepted+for+review+by+the+US+FDA/26781059.html Fri, 17 Jul 2026 01:22:00 -0400 A.06822034 CAMX CAMX CAMX CAMX O.01705570 O.20026344 http://www.streetinsider.com/PRNewswire/Camurus%27+NDA+resubmission+for+CAM2029+in+acromegaly+accepted+for+review+by+the+US+FDA/26781059.html <div class="xn-content"> <p><i>PDUFA target action date set to <chron>18 December 2026</chron></i></p><p><span class="legendSpanClass"><location value="LU/se..lund" idsrc="xmltag.org" >LUND, Sweden</location></span>, <span class="legendSpanClass"><chron>July 17, 2026</chron></span> /PRNewswire/ -- <span value="Stockholm:CAMX" idsrc="xmltag.org" >Camurus</span> (NASDAQ STO: CAMX) today announced that the <span value="ACORN:0682203466" idsrc="xmltag.org" >US Food and Drug Administration</span> (FDA) has accepted for review the resubmission of the New Drug Application (NDA) for CAM2029, octreotide extended-release injection, for the treatment of patients with acromegaly. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of <chron>18 December 2026</chron>.</p> <p>The resubmission follows the Complete Response Letter (CRL) issued by the FDA on <chron>10 June 2026</chron>, which related http://www.streetinsider.com/PRNewswire/Camurus%27+NDA+resubmission+for+CAM2029+in+acromegaly+accepted+for+review+by+the+US+FDA/26781059.html Fri, 17 Jul 2026 01:22:00 -0400 A.06822034 CAMX CAMX CAMX CAMX O.01705570 O.20026344 http://www.streetinsider.com/PRNewswire/Camurus%27+NDA+resubmission+for+CAM2029+in+acromegaly+accepted+for+review+by+the+US+FDA/26781059.html <div class="xn-content"> <p><i>PDUFA target action date set to <chron>18 December 2026</chron></i></p><p><span class="legendSpanClass"><location value="LU/se..lund" idsrc="xmltag.org" >LUND, Sweden</location></span>, <span class="legendSpanClass"><chron>July 17, 2026</chron></span> /PRNewswire/ -- <span value="Stockholm:CAMX" idsrc="xmltag.org" >Camurus</span> (NASDAQ STO: CAMX) today announced that the <span value="ACORN:0682203466" idsrc="xmltag.org" >US Food and Drug Administration</span> (FDA) has accepted for review the resubmission of the New Drug Application (NDA) for CAM2029, octreotide extended-release injection, for the treatment of patients with acromegaly. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of <chron>18 December 2026</chron>.</p> <p>The resubmission follows the Complete Response Letter (CRL) issued by the FDA on <chron>10 June 2026</chron>, which related http://www.streetinsider.com/PRNewswire/Camurus%27+NDA+resubmission+for+CAM2029+in+acromegaly+accepted+for+review+by+the+US+FDA/26781059.html Fri, 17 Jul 2026 01:22:00 -0400 A.06822034 CAMX CAMX CAMX CAMX O.01705570 O.20026344 http://www.streetinsider.com/General+News/Camurus+%28CAMX%29+announces+expansion+of+Lilly+collaboration%2C+decision+extends+Lilly%27s+exclusive%2C+global+rights+to+Camurus%27+FluidCrystal+technology/26581310.html <p>Camurus (NASDAQ STO: CAMX) today announced that Eli Lilly and Company ("Lilly") has exercised its option to include amylin receptor agonists (amylin) in the collaboration and license agreement entered in <chron>June 2025</chron>. The decision extends Lilly's exclusive, global rights to <span value="Stockholm:CAMX" idsrc="xmltag.org">Camurus'</span> FluidCrystal^® technology for the development and commercialization of long acting cardiometabolic drug medicines to an additional compound class.</p><p>The agreement comprises up to four proprietary Lilly drug compounds across three classes: dual <span>GLP-1</span> and GIP and receptor agonists, triple agonists for <span>GLP-1</span>, GIP and glucagon receptor agonists, and amylin receptor agonists.</p><p>"Lilly's decision to exercise the option validates our http://www.streetinsider.com/General+News/Camurus+%28CAMX%29+announces+expansion+of+Lilly+collaboration%2C+decision+extends+Lilly%27s+exclusive%2C+global+rights+to+Camurus%27+FluidCrystal+technology/26581310.html Mon, 01 Jun 2026 11:35:58 -0400 CAMX LLY http://www.streetinsider.com/General+News/Camurus+%28CAMX%29+announces+expansion+of+Lilly+collaboration%2C+decision+extends+Lilly%27s+exclusive%2C+global+rights+to+Camurus%27+FluidCrystal+technology/26581310.html <p>Camurus (NASDAQ STO: CAMX) today announced that Eli Lilly and Company ("Lilly") has exercised its option to include amylin receptor agonists (amylin) in the collaboration and license agreement entered in <chron>June 2025</chron>. The decision extends Lilly's exclusive, global rights to <span value="Stockholm:CAMX" idsrc="xmltag.org">Camurus'</span> FluidCrystal^® technology for the development and commercialization of long acting cardiometabolic drug medicines to an additional compound class.</p><p>The agreement comprises up to four proprietary Lilly drug compounds across three classes: dual <span>GLP-1</span> and GIP and receptor agonists, triple agonists for <span>GLP-1</span>, GIP and glucagon receptor agonists, and amylin receptor agonists.</p><p>"Lilly's decision to exercise the option validates our http://www.streetinsider.com/General+News/Camurus+%28CAMX%29+announces+expansion+of+Lilly+collaboration%2C+decision+extends+Lilly%27s+exclusive%2C+global+rights+to+Camurus%27+FluidCrystal+technology/26581310.html Mon, 01 Jun 2026 11:35:58 -0400 CAMX LLY http://www.streetinsider.com/Press+Releases/Camurus+announces+expansion+of+Lilly+collaboration/26581302.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/se..lund" idsrc="xmltag.org" >LUND, Sweden</location></span>, <span class="legendSpanClass"><chron>June 1, 2026</chron></span> /PRNewswire/ -- Camurus (NASDAQ STO: CAMX) today announced that Eli Lilly and Company ("Lilly") has exercised its option to include amylin receptor agonists (amylin) in the collaboration and license agreement entered in <chron>June 2025</chron>. The decision extends Lilly's exclusive, global rights to <span value="Stockholm:CAMX" idsrc="xmltag.org" >Camurus'</span> FluidCrystal^® technology for the development and commercialization of long acting cardiometabolic drug medicines to an additional compound class.</p> <p>The agreement comprises up to four proprietary Lilly drug compounds across three classes: dual <span>GLP-1</span> and GIP and receptor agonists, triple agonists for <span>GLP-1</span>, GIP and glucagon http://www.streetinsider.com/Press+Releases/Camurus+announces+expansion+of+Lilly+collaboration/26581302.html Mon, 01 Jun 2026 11:33:00 -0400 CAMX CAMX CAMX CAMX O.01705570 http://www.streetinsider.com/Press+Releases/Camurus+announces+expansion+of+Lilly+collaboration/26581302.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/se..lund" idsrc="xmltag.org" >LUND, Sweden</location></span>, <span class="legendSpanClass"><chron>June 1, 2026</chron></span> /PRNewswire/ -- Camurus (NASDAQ STO: CAMX) today announced that Eli Lilly and Company ("Lilly") has exercised its option to include amylin receptor agonists (amylin) in the collaboration and license agreement entered in <chron>June 2025</chron>. The decision extends Lilly's exclusive, global rights to <span value="Stockholm:CAMX" idsrc="xmltag.org" >Camurus'</span> FluidCrystal^® technology for the development and commercialization of long acting cardiometabolic drug medicines to an additional compound class.</p> <p>The agreement comprises up to four proprietary Lilly drug compounds across three classes: dual <span>GLP-1</span> and GIP and receptor agonists, triple agonists for <span>GLP-1</span>, GIP and glucagon http://www.streetinsider.com/Press+Releases/Camurus+announces+expansion+of+Lilly+collaboration/26581302.html Mon, 01 Jun 2026 11:33:00 -0400 CAMX CAMX CAMX CAMX O.01705570 http://www.streetinsider.com/Press+Releases/Camurus+announces+expansion+of+Lilly+collaboration/26581302.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/se..lund" idsrc="xmltag.org" >LUND, Sweden</location></span>, <span class="legendSpanClass"><chron>June 1, 2026</chron></span> /PRNewswire/ -- Camurus (NASDAQ STO: CAMX) today announced that Eli Lilly and Company ("Lilly") has exercised its option to include amylin receptor agonists (amylin) in the collaboration and license agreement entered in <chron>June 2025</chron>. The decision extends Lilly's exclusive, global rights to <span value="Stockholm:CAMX" idsrc="xmltag.org" >Camurus'</span> FluidCrystal^® technology for the development and commercialization of long acting cardiometabolic drug medicines to an additional compound class.</p> <p>The agreement comprises up to four proprietary Lilly drug compounds across three classes: dual <span>GLP-1</span> and GIP and receptor agonists, triple agonists for <span>GLP-1</span>, GIP and glucagon http://www.streetinsider.com/Press+Releases/Camurus+announces+expansion+of+Lilly+collaboration/26581302.html Mon, 01 Jun 2026 11:33:00 -0400 CAMX CAMX CAMX CAMX O.01705570 http://www.streetinsider.com/Press+Releases/Camurus+announces+expansion+of+Lilly+collaboration/26581302.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/se..lund" idsrc="xmltag.org" >LUND, Sweden</location></span>, <span class="legendSpanClass"><chron>June 1, 2026</chron></span> /PRNewswire/ -- Camurus (NASDAQ STO: CAMX) today announced that Eli Lilly and Company ("Lilly") has exercised its option to include amylin receptor agonists (amylin) in the collaboration and license agreement entered in <chron>June 2025</chron>. The decision extends Lilly's exclusive, global rights to <span value="Stockholm:CAMX" idsrc="xmltag.org" >Camurus'</span> FluidCrystal^® technology for the development and commercialization of long acting cardiometabolic drug medicines to an additional compound class.</p> <p>The agreement comprises up to four proprietary Lilly drug compounds across three classes: dual <span>GLP-1</span> and GIP and receptor agonists, triple agonists for <span>GLP-1</span>, GIP and glucagon http://www.streetinsider.com/Press+Releases/Camurus+announces+expansion+of+Lilly+collaboration/26581302.html Mon, 01 Jun 2026 11:33:00 -0400 CAMX CAMX CAMX CAMX O.01705570 http://www.streetinsider.com/Press+Releases/Camurus+announces+expansion+of+Lilly+collaboration/26581302.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/se..lund" idsrc="xmltag.org" >LUND, Sweden</location></span>, <span class="legendSpanClass"><chron>June 1, 2026</chron></span> /PRNewswire/ -- Camurus (NASDAQ STO: CAMX) today announced that Eli Lilly and Company ("Lilly") has exercised its option to include amylin receptor agonists (amylin) in the collaboration and license agreement entered in <chron>June 2025</chron>. The decision extends Lilly's exclusive, global rights to <span value="Stockholm:CAMX" idsrc="xmltag.org" >Camurus'</span> FluidCrystal^® technology for the development and commercialization of long acting cardiometabolic drug medicines to an additional compound class.</p> <p>The agreement comprises up to four proprietary Lilly drug compounds across three classes: dual <span>GLP-1</span> and GIP and receptor agonists, triple agonists for <span>GLP-1</span>, GIP and glucagon http://www.streetinsider.com/Press+Releases/Camurus+announces+expansion+of+Lilly+collaboration/26581302.html Mon, 01 Jun 2026 11:33:00 -0400 CAMX CAMX CAMX CAMX O.01705570 http://www.streetinsider.com/PRNewswire/Camurus+announces+expansion+of+Lilly+collaboration/26581302.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/se..lund" idsrc="xmltag.org" >LUND, Sweden</location></span>, <span class="legendSpanClass"><chron>June 1, 2026</chron></span> /PRNewswire/ -- Camurus (NASDAQ STO: CAMX) today announced that Eli Lilly and Company ("Lilly") has exercised its option to include amylin receptor agonists (amylin) in the collaboration and license agreement entered in <chron>June 2025</chron>. The decision extends Lilly's exclusive, global rights to <span value="Stockholm:CAMX" idsrc="xmltag.org" >Camurus'</span> FluidCrystal^® technology for the development and commercialization of long acting cardiometabolic drug medicines to an additional compound class.</p> <p>The agreement comprises up to four proprietary Lilly drug compounds across three classes: dual <span>GLP-1</span> and GIP and receptor agonists, triple agonists for <span>GLP-1</span>, GIP and glucagon http://www.streetinsider.com/PRNewswire/Camurus+announces+expansion+of+Lilly+collaboration/26581302.html Mon, 01 Jun 2026 11:33:00 -0400 CAMX CAMX CAMX CAMX O.01705570 http://www.streetinsider.com/PRNewswire/Camurus+announces+expansion+of+Lilly+collaboration/26581302.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/se..lund" idsrc="xmltag.org" >LUND, Sweden</location></span>, <span class="legendSpanClass"><chron>June 1, 2026</chron></span> /PRNewswire/ -- Camurus (NASDAQ STO: CAMX) today announced that Eli Lilly and Company ("Lilly") has exercised its option to include amylin receptor agonists (amylin) in the collaboration and license agreement entered in <chron>June 2025</chron>. The decision extends Lilly's exclusive, global rights to <span value="Stockholm:CAMX" idsrc="xmltag.org" >Camurus'</span> FluidCrystal^® technology for the development and commercialization of long acting cardiometabolic drug medicines to an additional compound class.</p> <p>The agreement comprises up to four proprietary Lilly drug compounds across three classes: dual <span>GLP-1</span> and GIP and receptor agonists, triple agonists for <span>GLP-1</span>, GIP and glucagon http://www.streetinsider.com/PRNewswire/Camurus+announces+expansion+of+Lilly+collaboration/26581302.html Mon, 01 Jun 2026 11:33:00 -0400 CAMX CAMX CAMX CAMX O.01705570 http://www.streetinsider.com/PRNewswire/Camurus+announces+expansion+of+Lilly+collaboration/26581302.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/se..lund" idsrc="xmltag.org" >LUND, Sweden</location></span>, <span class="legendSpanClass"><chron>June 1, 2026</chron></span> /PRNewswire/ -- Camurus (NASDAQ STO: CAMX) today announced that Eli Lilly and Company ("Lilly") has exercised its option to include amylin receptor agonists (amylin) in the collaboration and license agreement entered in <chron>June 2025</chron>. The decision extends Lilly's exclusive, global rights to <span value="Stockholm:CAMX" idsrc="xmltag.org" >Camurus'</span> FluidCrystal^® technology for the development and commercialization of long acting cardiometabolic drug medicines to an additional compound class.</p> <p>The agreement comprises up to four proprietary Lilly drug compounds across three classes: dual <span>GLP-1</span> and GIP and receptor agonists, triple agonists for <span>GLP-1</span>, GIP and glucagon http://www.streetinsider.com/PRNewswire/Camurus+announces+expansion+of+Lilly+collaboration/26581302.html Mon, 01 Jun 2026 11:33:00 -0400 CAMX CAMX CAMX CAMX O.01705570 http://www.streetinsider.com/PRNewswire/Camurus+announces+expansion+of+Lilly+collaboration/26581302.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/se..lund" idsrc="xmltag.org" >LUND, Sweden</location></span>, <span class="legendSpanClass"><chron>June 1, 2026</chron></span> /PRNewswire/ -- Camurus (NASDAQ STO: CAMX) today announced that Eli Lilly and Company ("Lilly") has exercised its option to include amylin receptor agonists (amylin) in the collaboration and license agreement entered in <chron>June 2025</chron>. The decision extends Lilly's exclusive, global rights to <span value="Stockholm:CAMX" idsrc="xmltag.org" >Camurus'</span> FluidCrystal^® technology for the development and commercialization of long acting cardiometabolic drug medicines to an additional compound class.</p> <p>The agreement comprises up to four proprietary Lilly drug compounds across three classes: dual <span>GLP-1</span> and GIP and receptor agonists, triple agonists for <span>GLP-1</span>, GIP and glucagon http://www.streetinsider.com/PRNewswire/Camurus+announces+expansion+of+Lilly+collaboration/26581302.html Mon, 01 Jun 2026 11:33:00 -0400 CAMX CAMX CAMX CAMX O.01705570